Table 5.
EUD of CTV_CW/Breast, CTV_IMN, and CTV_SCVN in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer.
| Patient # | CTV_CW/Breast | CTV_IMN | CTV_SCVN | ||||||
|---|---|---|---|---|---|---|---|---|---|
| EUD (Gy(RBE) | EUD (Gy(RBE) | EUD (Gy(RBE) | |||||||
| PB‐PB | PB‐MC | MC‐MC | PB‐PB | PB‐MC | MC‐MC | PB‐PB | PB‐MC | MC‐MC | |
| 1 | 50.7 | 48.9 | 50.7 | 51.1 | 49.1 | 51.1 | 51.3 | 48.1 | 51.3 |
| 2 | 51.3 | 49.6 | 51.0 | 51.0 | 48.3 | 51.0 | 51.2 | 48.8 | 51.7 |
| 3 | 50.4 | 48.3 | 50.2 | 50.2 | 44.7 | 49.7 | 50.2 | 47.3 | 50.0 |
| 4 | 49.1 | 47.1 | 49.0 | 49.3 | 46.1 | 49.1 | 49.0 | 45.8 | 48.8 |
| 5 | 50.2 | 48.5 | 49.2 | 51.4 | 47.8 | 50.7 | 51.4 | 48.3 | 50.8 |
| 6 | 49.1 | 47.1 | 49.0 | 49.3 | 46.1 | 49.1 | 49.0 | 45.8 | 48.8 |
| 7 | 50.9 | 48.4 | 51.0 | 52.1 | 48.9 | 52.0 | 51.0 | 47.1 | 50.6 |
| 8 | 51.0 | 49.4 | 50.1 | 51.1 | 48.1 | 50.3 | 51.1 | 48.2 | 49.9 |
| 9 | 50.7 | 49.2 | 49.9 | 48.9 | 46.0 | 47.8 | 50.7 | 47.6 | 49.8 |
| 10 | 50.8 | 48.7 | 50.7 | 50.5 | 47.5 | 50.4 | 50.6 | 47.2 | 50.6 |
| Average | 50.4 | 48.5 | 50.1 | 50.5 | 47.3 | 50.1 | 50.5 | 47.4 | 50.2 |
| SD | 0.7 | 0.9 | 0.8 | 1.0 | 1.5 | 1.2 | 0.9 | 1.0 | 1.0 |
| P‐value | <0.001 | 0.289 | <0.001 | 0.447 | <0.001 | 0.327 | |||
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed by MC dose calculation; CTV, clinical target volume; CW, chestwall; EUD, equivalent uniform dose; IMN, internal mammary nodes; SCVN, supraclavicular nodes; RBE, relative biological effectiveness.
P‐value for PB‐MC vs. PB‐PB.
P‐value for MC‐MC vs. PB‐PB.